Jones Financial Companies’s Gain Therapeutics GANX Stock Holding History

Jones Financial Companies’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Sell	608,592 -23,023	-4%	-$42.4K	﹤0.01%	1863
2026 Q1	$1.16M	Sell	631,615 -70,598	-10%	-$154K	﹤0.01%	1659
2025 Q4	$2.26M	Buy	702,213 +25,391	+4%	+$67.8K	﹤0.01%	894
2025 Q3	$1.21M	Sell	676,822 -66	-0%	-$111	﹤0.01%	1061
2025 Q2	$1.33M	Buy	676,888 +249,188	+58%	+$461K	﹤0.01%	899
2025 Q1	$808K	Buy	427,700 +329,450	+335%	+$731K	﹤0.01%	944
2024 Q4	$212K	Buy	98,250 +44,750	+84%	+$89.8K	﹤0.01%	1327
2024 Q3	$106K	Buy	53,500 +46,500	+664%	+$58.4K	﹤0.01%	1376
2024 Q2	$8.96K	Buy	+7,000	New	+$18.2K	﹤0.01%	1788

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jones Financial Companies's GANX Position: Q2 2026 in Review

Jones Financial Companies reduced its Gain Therapeutics (GANX) stake by 3.6% in Q2 2026, selling an estimated $42.4K and leaving 608,592 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

Jones Financial Companies first reported a position in GANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.26M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Jones Financial Companies held 608,592 shares of Gain Therapeutics worth $1.07M as of Q2 2026.
Jones Financial Companies sold 23,023 Gain Therapeutics shares in Q2 2026, an estimated $42.4K.
Gain Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1863 holding.
Jones Financial Companies first reported a position in Gain Therapeutics in Q2 2024 and has held it in 9 quarters since.
Jones Financial Companies's Gain Therapeutics position peaked at $2.26M in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.